RDY

Dr Reddy's Laboratories Ltd

Add to Watchlist

Advanced Chart

13.820

+0.02(0.145%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

13.890

Open

13.830

VWAP

13.81

Vol

781.31K

Mkt Cap

11.50B

Low

13.7725

Amount

10.79M

EV/EBITDA(TTM)

11.41

Total Shares

166.54M

1.00T

EV/OCF(TTM)

P/S(TTM)

3.04

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

86.10B

+1.22%

18.311

+15.71%

84.87B

+1.54%

19.089

+14.33%

Estimates Revision

The market is revising Upward the revenue expectations for Dr. Reddy's Laboratories Limited (RDY) for FY2026, with the revenue forecasts being adjusted by 0.8% over the past three months. During the same period, the stock price has changed by -0.79%.

Revenue Estimates for FY2026

Revise Upward

+0.8%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-3.42%

In Past 3 Month

Stock Price

Go Down

-0.79%

In Past 3 Month

2 Analyst Rating

17.22% Upside

Wall Street analysts forecast RDY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RDY is 16.20 USD with a low forecast of 15.50 USD and a high forecast of 16.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

17.22% Upside

Current: 13.820

Low

15.50

Averages

16.20

High

16.90

17.22% Upside

Current: 13.820

Low

15.50

Averages

16.20

High

16.90

HSBC

Hold

Buy

upgrade

2025-06-05

Reason

HSBC

Price Target

2025-06-05

upgrade

Hold

Buy

Reason

HSBC upgraded Dr. Reddy's to Buy from Hold with a price target of $16.90, up from $14.44. The firm believes semaglutide sales will help Dr. Reddy's to return to earnings growth path within a year of launch in key markets. While a recent court order in India has restrained Dr. Reddy's launch of semaglutide in export markets until the patent expiry of the reference brand in India in March 2026, the company will be among the first companies to launch in key markets opening up in 2026, the analyst tells investors in a research note. The firm sees a semaglutide-led earnings recovery for the company.

Barclays

Balaji Prasad

Buy

Maintains

$17 → $17

2024-11-06

Reason

Barclays

Balaji Prasad

Price Target

$17 → $17

2024-11-06

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Dr Reddy's Laboratories Ltd (RDY.N) is 18.66, compared to its 5-year average forward P/E of 20.95. For a more detailed relative valuation and DCF analysis to assess Dr Reddy's Laboratories Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

20.95

Current PE

18.66

Overvalued PE

25.59

Undervalued PE

16.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

12.76

Current EV/EBITDA

11.91

Overvalued EV/EBITDA

15.25

Undervalued EV/EBITDA

10.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

3.28

Current PS

2.91

Overvalued PS

3.68

Undervalued PS

2.87